bioAffinity Technologies has published a company-authored clinical review proposing how its CyPath Lung sputum test could be incorporated into pulmonary nodule assessment across primary care, pulmonology and oncology practices. The Nasdaq-listed diagnostics company is attempting to convert three years of commercial experience into repeatable clinical workflows, particularly for patients whose imaging, predictive models and individual risk factors produce uncertain or conflicting conclusions. The publication is a clinical white paper rather than a newly peer-reviewed prospective trial report, meaning it advances the implementation argument for CyPath Lung without independently expanding the underlying validation dataset.
The framework, written by bioAffinity Technologies Chief Medical Officer Gordon H. Downie, covers patients with incidentally discovered pulmonary nodules, people being considered for invasive biopsy and cancer survivors undergoing surveillance. Management positions CyPath Lung as an additional biological signal that can complement imaging and clinical judgement, not as a replacement for established guidelines or physician interpretation.
That distinction matters. The commercial opportunity around pulmonary nodule risk stratification is considerable because wider low-dose computed tomography screening, incidental imaging findings and increasingly sensitive image-analysis systems are identifying more nodules. Yet the central clinical challenge is not merely detecting a nodule. It is deciding whether that nodule warrants serial imaging, positron emission tomography, tissue sampling, surgery or continued observation without exposing patients to avoidable procedural risks.
What is genuinely new in bioAffinity Technologies’ CyPath Lung clinical framework?
The main development is not a redesign of CyPath Lung or the release of a new clinical performance study. It is bioAffinity Technologies’ effort to define where the test should sit within three different clinical environments, each of which has distinct decision points, referral patterns and tolerance for uncertainty.
In primary care, the proposed role is to provide additional information when a pulmonary nodule is discovered incidentally and the physician must determine whether specialist referral or intensified surveillance is justified. In pulmonary nodule and interventional pulmonology programmes, the test is positioned nearer the biopsy decision, where avoiding an unnecessary invasive procedure could have meaningful clinical and economic value. For oncology practices, bioAffinity Technologies is proposing a potentially broader application in the surveillance of people previously treated for cancer.
Creating specialty-specific protocols could lower an important commercial barrier. Diagnostics often struggle not because physicians cannot understand their technology, but because clinicians are uncertain about when to order the test, which patients are appropriate and how a result should alter management. A practical workflow can therefore be commercially useful even when it does not constitute new clinical evidence.
However, the framework remains authored by the company’s chief medical officer and is supported partly by selected case studies from commercial use. Those cases may illustrate plausible clinical value, but they do not provide the denominator-based evidence needed to determine how frequently CyPath Lung changes management correctly, how often it produces misleading results or whether its use improves outcomes across a wider population.
How mature is the clinical evidence supporting CyPath Lung for small lung nodules?
CyPath Lung’s principal peer-reviewed validation was published in Respiratory Research in 2023. Researchers developed an automated flow cytometry and machine-learning model using sputum samples from 150 high-risk patients, including 28 with lung cancer, before testing the final model in a second independent group of 32 samples that included six cancers.
In the main cohort, the model reported 82% sensitivity, 88% specificity, a 96% negative predictive value and a 61% positive predictive value. Within the subgroup of patients with nodules smaller than 20 millimetres, sensitivity reached 92% and specificity was 87%. The smaller independent dataset produced 83% sensitivity, 77% specificity, a 95% negative predictive value and a 45% positive predictive value.
bioAffinity Technologies frequently highlights a 99% negative predictive value for high-risk patients with small nodules. That figure may be clinically attractive because the test is partly intended to support decisions to monitor rather than immediately biopsy. Nevertheless, negative predictive value depends on disease prevalence and the characteristics of the tested population. It should not automatically be expected across primary care, specialist pulmonary clinics and post-cancer surveillance populations, where baseline cancer probabilities may differ substantially.
The validation study provides a meaningful signal that sputum flow cytometry combined with automated analysis can distinguish cancer from non-cancer samples. Its limitations are equally important. The number of confirmed cancers was modest, the independent validation group contained only six cancers and the study did not prospectively test whether using CyPath Lung reduced unnecessary procedures without delaying diagnoses.
A diagnostic can demonstrate sensitivity and specificity without proving clinical utility. The stronger commercial and clinical question is whether adding the test to imaging, risk calculators and physician assessment results in fewer benign biopsies, fewer missed malignancies, shorter diagnostic delays or better use of specialist resources.
Why could sputum analysis complement imaging and blood-based lung cancer tests?
CyPath Lung examines material collected from the respiratory tract rather than relying on a blood sample. Patients collect sputum at home over three days, after which Precision Pathology Laboratory Services uses flow cytometry to analyse cell populations, immune characteristics, viability markers and uptake of a fluorescent porphyrin associated with cancer-related cells. Automated analysis then combines assay features with patient information to generate the result.
The biological proposition is that sputum may contain cellular and immune information originating directly from the lung microenvironment. This could be particularly relevant in small or early-stage lesions that may release limited circulating tumour material into the bloodstream. It also gives CyPath Lung a differentiated story at a time when many competing early cancer detection strategies are concentrating on blood-based biomarkers.
That differentiation should not be interpreted as demonstrated superiority. Sputum collection introduces its own operational variables, including whether patients can provide adequate samples, whether cells remain suitable during transportation and how consistently the process performs across different healthcare environments. The three-day home collection model is noninvasive, but compliance and sample quality will influence real-world scalability.
A 2026 review of sputum-based liquid biopsy research described the field as promising but also identified substantial variation in collection methods, processing techniques and analytical platforms. The review found limited prospective validation, few direct comparisons with blood-based methods and insufficient evidence showing an effect on patient outcomes. That broader assessment reinforces why CyPath Lung’s next validation programme matters more than isolated commercial case reports.
Where could CyPath Lung realistically fit within pulmonary nodule management pathways?
The United States Preventive Services Task Force recommends annual low-dose computed tomography for adults aged 50 to 80 who have at least a 20 pack-year smoking history and either continue to smoke or quit within the previous 15 years. The task force has also emphasised that the benefit of screening depends partly on resolving most false-positive results through serial imaging rather than unnecessary invasive procedures.
Current pulmonary nodule pathways already combine nodule size, growth, morphology, smoking exposure, age and other clinical characteristics. Depending on estimated malignancy risk, clinicians may choose follow-up imaging, positron emission tomography, biopsy, surgical evaluation or multidisciplinary review. CyPath Lung is therefore entering an established decision architecture rather than filling a completely empty space.
Its most plausible near-term use may be in intermediate-risk cases where imaging and conventional predictive models do not provide a comfortable answer. A reassuring result could support continued imaging surveillance in a patient with elevated procedural risk, while a concerning result might strengthen the case for biopsy when other findings are equivocal.
Neither outcome should be interpreted in isolation. bioAffinity Technologies states that CyPath Lung is not intended as a sole diagnostic tool, and the company’s own reporting materials caution that a negative result does not exclude abnormality and that a positive result does not independently establish cancer.
The proposed oncology-surveillance pathway is strategically interesting but requires population-specific evidence. Cancer survivors can have different baseline risks, treatment-related lung changes and imaging abnormalities from screening populations. Performance established in high-risk smokers with indeterminate nodules cannot automatically be transferred to people previously treated for lung cancer or another malignancy.
What does CyPath Lung’s laboratory-developed test status mean for adoption?
CyPath Lung is marketed by Precision Pathology Laboratory Services as a laboratory-developed test performed in a laboratory certified under the Clinical Laboratory Improvement Amendments. It has not received United States Food and Drug Administration clearance or approval.
The wider federal environment for laboratory-developed tests changed after a district court vacated the United States Food and Drug Administration’s 2024 final rule asserting broader medical-device oversight. In September 2025, the agency restored the relevant regulation to its wording before the vacated rule. That development removed the phased framework contemplated by the 2024 rule, but it did not represent an agency review or endorsement of CyPath Lung’s clinical performance.
The absence of a conventional premarket clearance requirement can facilitate commercial availability, but it shifts much of the adoption test toward clinical evidence, laboratory quality, reimbursement and physician confidence. Clinical Laboratory Improvement Amendments certification addresses laboratory operations and testing standards. It should not be interpreted as independent proof that using the assay improves patient outcomes.
bioAffinity Technologies says results are generally returned within three days after the laboratory receives the sample and that Medicare and private insurance are accepted. Its physician materials also acknowledge that coverage varies, prior authorisation may be required and full payment is not guaranteed. A dedicated billing code can support claims processing, but a code alone does not ensure that payers will cover the test broadly or at an economically sustainable rate.
Can rising CyPath Lung sales overcome bioAffinity Technologies’ financing pressure?
The clinical framework arrives while bioAffinity Technologies is reporting stronger unit growth from a relatively small commercial base. The company said second-quarter 2026 CyPath Lung test volumes increased by more than 200% from the prior-year period and more than 30% sequentially. The number of physician offices placing orders rose 155% year over year, while cumulative commercial volume approached 3,000 tests.
First-quarter CyPath Lung testing revenue rose 114% to approximately $361,000, although consolidated revenue declined 36% to $1.4 million. The company recorded a quarterly net loss of $3.6 million and said its cash and anticipated operating revenue were expected to support operations only through June 2026 at the time of the filing.
bioAffinity Technologies subsequently completed a public offering that generated approximately $3.2 million in gross proceeds through shares and pre-funded warrants priced at $0.80 and $0.793, respectively. The financing provided additional working capital, but it also increased the share base and underlined the company’s continuing reliance on external capital while it attempts to scale diagnostic revenue.
Nasdaq-listed bioAffinity Technologies shares closed at $0.6817 on July 27, up 3.3% during the session in which the clinical framework was announced. The stock was approximately 3% below its July 20 close and around 15% below its June 29 close, remaining below the June offering price and near the lower end of its 52-week trading range. The pattern suggests that investors continue to treat CyPath Lung as an early commercial opportunity carrying meaningful financing, validation and execution risk rather than as a fully de-risked diagnostics franchise.
What evidence will determine whether the new framework influences routine care?
The most consequential programme is bioAffinity Technologies’ planned large longitudinal study of patients with lung nodules measuring more than 6 millimetres and less than 30 millimetres. The ClinicalTrials.gov record lists a targeted enrolment of 2,063 participants and a 24-month follow-up period, with estimated final completion in July 2029. The company reported in its first-quarter filing that the first patient had been enrolled in March 2026, although the registry page was last updated in September 2025 and still displayed an earlier recruitment status.
A study of that scale could provide more reliable estimates of sensitivity and specificity across nodule sizes, patient subgroups and clinical settings. The more valuable analysis would go further by measuring sample failure rates, biopsy decisions, benign procedure rates, missed or delayed diagnoses and the extent to which physicians actually follow recommendations informed by the result.
Payers and professional societies will also want evidence that CyPath Lung adds information beyond established risk calculators, imaging characteristics and clinical judgement. Demonstrating statistical performance is necessary, but adoption is more likely to depend on whether the test produces decisions that are safer, more efficient and economically defensible.
The new white paper gives bioAffinity Technologies a clearer commercial narrative and may help physicians understand where CyPath Lung could be ordered. It does not, by itself, settle the harder question of whether the test should become a routine part of pulmonary nodule management. That answer will depend on prospective validation, reproducible performance outside early adopter practices, dependable reimbursement and proof that adding sputum-based lung microenvironment analysis improves the balance between timely cancer detection and avoidance of unnecessary invasive procedures.
